A double-blind, placebo-controlled trial of modafinil (200 mg/day) for methamphetamine dependence
Shearer J, Darke S, Rodgers C, Slade T, van Beek I, Lewis J,
Brady D, McKetin R, Mattick RP, Wodak A.
National Drug and Alcohol Research Centre,
University of New South Wales,
Sydney, NSW, Australia. Addiction. 2009 Feb;104(2):224-33.


AIM: To examine the safety and efficacy of modafinil (200 mg/day) compared to placebo in the treatment of methamphetamine dependence and to examine predictors of post-treatment outcome. PARTICIPANTS AND DESIGN: Eighty methamphetamine-dependent subjects in Sydney, Australia were allocated randomly to modafinil (200 mg/day) (n = 38) or placebo (n = 42) under double-blind conditions for 10 weeks with a further 12 weeks post-treatment follow-up. MEASURES: Comprehensive drug use data (urine specimens and self-report) and other health and psychosocial data were collected weekly during treatment and research interviews at baseline, week 10 and week 22. RESULTS: Treatment retention and medication adherence were equivalent between groups. There were no differences in methamphetamine abstinence, craving or severity of dependence. Medication-compliant subjects tended to provide more methamphetamine-negative urine samples over the 10-week treatment period (P = 0.07). Outcomes were better for methamphetamine-dependent subjects with no other substance dependence and those who accessed counselling. There were statistically significant reductions in systolic blood pressure (P = 0.03) and weight gain (P = 0.05) in modafinil-compliant subjects compared to placebo. There were no medication-related serious adverse events. Adverse events were generally mild and consistent with known pharmacological effects. CONCLUSIONS: Modafinil demonstrated promise in reducing methamphetamine use in selected methamphetamine-dependent patients. The study findings support definitive trials of modafinil in larger multi-site trials.

The sleep-switch
Modafinil: structure
Atypical depression
Modafinil and the aviator
Modafinil: pharmacokinetics
Modafinil and the marmoset
Modafinil wakes up sleepy flies
Modafinil versus amphetamine
Modafinil versus methylphenidate
Modafinil v amphetamine v placebo
Fatigue, sleepiness in major depression
Modafinil plus SSRIs for depression and fatigue
Dosing regimen effects of modafinil in narcolepsy
Mood-lifting effect of caloric restriction is mediated by orexin
Modafinil plus selective serotonin reuptake inhibitors (SSRIs)
Modafinil: a dual noradrenergic-dopaminergic mechanism of action?

and further reading

Future Opioids
BLTC Research
The Abolitionist Project
The Hedonistic Imperative
MDMA: Utopian Pharmacology

The Good Drug Guide
The Responsible Parent's Guide
To Healthy Mood Boosters For All The Family